Eurofins Scientific SE's EBIT per Share for the
six
months ended in Dec. 2025 was $2.50.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $5.05.
During the past 12 months, the average EBIT per Share Growth Rate of Eurofins Scientific SE was 17.50% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 3.70% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -4.50% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 13.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Eurofins Scientific SE's EBIT per Share or its related term are showing as below:
ERFSF'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -22.5 Med: 25.8 Max: 80.8
Current: 3.7
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Eurofins Scientific SE was 80.80% per year. The lowest was -22.50% per year. And the median was 25.80% per year.
ERFSF's 3-Year EBIT Growth Rate is ranked worse than 61.9% of 168
companies
in the Medical Diagnostics & Research industry
Industry Median: 12.75
vs ERFSF: 3.70
Eurofins Scientific SE (OTCPK:ERFSF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Eurofins Scientific SE EBIT per Share Related Terms
Eurofins Scientific SE EBIT per Share Historical Data
* Premium members only.
The historical data trend for Eurofins Scientific SE's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $5.05
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eurofins Scientific SE (ERFSF) has a EBIT per Share of $5.05 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Eurofins Scientific SE and its competitors. According to the industry distribution chart, Eurofins Scientific SE ranks #104 out of 168 companies in the Medical Diagnostics & Research industry, placing it in the top 61.9%.
Is Eurofins Scientific SE's EBIT per Share too high?
Eurofins Scientific SE's current EBIT per Share is $5.05. The Medical Diagnostics & Research industry median EBIT per Share is 12.75. Eurofins Scientific SE's value of $5.05 is 60.4% below this industry median. Based on the distribution chart, Eurofins Scientific SE ranks #104 out of 168 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Eurofins Scientific SE has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Eurofins Scientific SE's EBIT per Share compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Eurofins Scientific SE ranks #104 out of 168 companies for EBIT per Share. This places Eurofins Scientific SE in the lower half of its industry. The industry median EBIT per Share is 12.75. Eurofins Scientific SE's value of $5.05 is 60.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Diagnostics & Research company?
The median EBIT per Share among Medical Diagnostics & Research companies is 12.75, based on 168 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eurofins Scientific SE's current EBIT per Share of $5.05 is 60.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Eurofins Scientific SE and its competitors. For the Medical Diagnostics & Research industry, the median EBIT per Share is 12.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eurofins Scientific SE's current EBIT per Share is $5.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eurofins Scientific SE stock overvalued right now?
Based on GuruFocus' analysis, Eurofins Scientific SE (ERFSF) is currently considered Fairly Valued. The stock's GF Value™ is $77.44, compared to a current price of $79.77 — trading 3% above its estimated fair value. The current EBIT per Share is $5.05 and 60.4% below the Medical Diagnostics & Research industry median of 12.75. Eurofins Scientific SE's overall GF Score™ is 77/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Eurofins Scientific SE (ERFSF), the current EBIT per Share is $5.05 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eurofins Scientific SE (ERFSF) Overvalued in 2026?
Based on GuruFocus' analysis, Eurofins Scientific SE stock appears to be overvalued.
The current stock price of $79.77 is trading 3% above its estimated GF Value™ of $77.44.
GuruFocus considers Eurofins Scientific SE to be Fairly Valued.
Key valuation signals for ERFSF:
EBIT per Share: $5.05
GF Value™: $77.44 vs. price of $79.77 (3% above fair value)
Industry Position: 60.4% below the Medical Diagnostics & Research median (#104 of 168)
No single metric tells the full story. See the ERFSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eurofins, headquartered in Luxembourg, is a decentralized network of life sciences companies that provide various analytical tests and laboratory services. These include tests to evaluate the safety, identity, composition, authenticity, purity, origin, and traceability of various biological substances and products. Eurofins operates over 950 laboratories in 61 countries. Its revenue from Europe, North America, and the rest of the world contributes approximately 50%, 40%, and 10% of total revenue, respectively. Its areas of business activity are food, feed, and environmental testing ("life"), biopharmaceutical services, diagnostic services and products, and consumer and technology products testing, which contribute approximately 40%, 30%, 20%, and 10% respectively.
77GF Score
Get the complete analysis for ERFSF
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ERFSF has been successfully added to your 
